6 |
INDUSTRY INSIGHTS ................................................................................................................ 47 |
|||
• 6.1 |
INTRODUCTION ............................................................................................................................................................... 48 |
|||
• 6.2 |
INDUSTRY TRENDS ......................................................................................................................................................... 48 |
|||
• 6.2.1 |
GROWING MARKET DEMAND FOR HUMAN INSULIN PENS ......................................................................... 48 |
|||
• 6.2.2 |
INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF |
|||
NOVEL HUMAN INSULIN THERAPIES ........................................................................................................... 49 | ||||
• 6.3 |
PIPELINE ANALYSIS ......................................................................................................................................................... 51 |
|||
• 6.3.1 |
BY COMPANY ................................................................................................................................................ 51 |
|||
• 6.3.2 |
BY CLINICAL TRIAL PHASE ........................................................................................................................... 52 |
|||
• 6.3.3 |
PORTER ’ S FIVE FORCE ANALYSIS ................................................................................................................. 53 |
|||
• 6.3.3.1 |
THREAT FROM NEW ENTRANTS .............................................................................................. 54 |
|||
• 6.3.3.2 |
THREAT FROM SUBSTITUTES .................................................................................................. 54 |
|||
• 6.3.3.3 |
BARGAINING POWER OF BUYERS ........................................................................................... 54 |
|||
• 6.3.3.4 |
BARGAINING POWER OF SUPPLIERS ...................................................................................... 55 |
|||
• 6.3.3.5 |
INTENSITY OF COMPETITIVE RIVALRY .................................................................................... 55 |
|||
7 |
GLOBAL HUMAN INSULIN MARKET , BY PRODUCT TYPE ......................................................... 56 |
|
• 7.1 |
INTRODUCTION ............................................................................................................................................................... 57 |
|
• 7.2 |
HUMAN INSULIN DRUGS ................................................................................................................................................ 58 |
|
• 7.3 |
HUMAN INSULIN DELIVERY DEVICES ............................................................................................................................. 59 |
|
8 |
GLOBAL HUMAN INSULIN DRUGS MARKET , BY TYPE ............................................................. 61 |
||
• 8.1 |
INTRODUCTION ............................................................................................................................................................... 62 |
||
• 8.2 |
INSULIN ANALOGS AND BIOSIMILARS ........................................................................................................................... 62 |
||
• 8.2.1 |
LONG-ACTING ............................................................................................................................................... 64 |
||
• 8.2.2 |
RAPID-ACTING .............................................................................................................................................. 66 |
||
• 8.2.3 |
PREMIXED ..................................................................................................................................................... 67 |
||
• 8.3 |
HUMAN INSULIN BIOLOGICS .......................................................................................................................................... 68 |
||
• 8.3.1 |
SHORT-ACTING ............................................................................................................................................. 70 |
||
• 8.3.2 |
INTERMEDIATE-ACTING ................................................................................................................................ 71 |
||
• 8.3.3 |
PREMIXED ..................................................................................................................................................... 72 |
||
• | |||